@article{aabbba55d85446f8b7b70862184cdcef,
title = "Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool",
author = "Manuel Carcao and Laura Zunino and Young, {Nancy L.} and Saunya Dover and Vanessa Bouskill and Pamela Hilliard and Price, {Victoria E.} and Blanchette, {Victor S.}",
note = "Funding Information: M. Carcao: Reports having received research support from Bayer, Bioverativ/Sanofi, CSL Behring, Novo Nordisk, Octapharma, Pfizer and Shire. He has also received honoraria for speaking/participating in advisory boards from Bayer, Bioverativ/Sanofi, Biotest, CSL Behring, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche and Shire. L. Zunino reports no conflicts. N. Young reports no conflicts. S. Dover reports no conflicts. V. Bouskill reports no conflicts. P. Hilliard: Reports acting as a paid consultant for Alnylam and Pfizer. V. Price reports no conflicts. VS Blanchette: Reports receiving speakers fees/honoraria for participation in Educational events/Advisory Boards from Bayer Health Care, Bioverativ/Sonofi, Novo Nordisk, Pfizer, Roche, Shire and Spark Therapeutics. Member of Data Safety Monitoring Boards for Octapharma and Shire. Research Grants from Bayer Health Care, Bioverativ and Shire. Chairman of the International Prophylaxis Study Group (IPSG), a non‐for‐profit collaborative study group supported by grants from Bayer Health Care, Bioverativ, Novo Nordisk, Pfizer, Shire and Spark Therapeutics to the Hospital for Sick Children Foundation, Toronto, Canada. Publisher Copyright: {\textcopyright} 2019 John Wiley & Sons Ltd",
year = "2020",
month = jan,
day = "1",
doi = "10.1111/hae.13905",
language = "English",
volume = "26",
pages = "73--78",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "1",
}